A popular prostate cancer treatment called androgen deprivation therapy may encourage prostate cancer cells to produce a protein that makes them more likely to spread throughout the body, a new study by Johns Hopkins researchers suggests.
Ontario Liberals will take another step forward in its battle against cancer by covering prostate specific antigen (PSA) tests for men over the age of 50, said Health Minister George Smitherman from the Columbus Centre Fitness Club.
About a third of American adults take some type of multivitamin on a regular basis. In nearly every case, the goal is better health, even though there is no firm evidence to support this hope.
The part of the prostate that is biopsied may matter more than the number of biopsy samples taken for accurately diagnosing prostate cancer.
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).
Recent investigations of medications, diet and the molecular understanding of prostate cancer are defining potential prevention strategies for the disease, and herald a new stage in the management of this cancer, according to a new review.
Ontario’s 2,850,000 men over the age of 40 will be able to have a free PSA test if the Liberals are elected next month. As part of their election health initiative, the Liberals will have OHIP pick up the cost of the test. Currently it costs men in Ontario between $20 and $35 to have the test done.
A University of Minnesota study of prostate cancer tumors from Caucasian and African-American men has shown no evidence that the cancer is more aggressive in black men. Lead investigator Akhouri Sinha, a professor of genetics, cell biology, and development and research scientist at the Minneapolis VA Medical Center, said the belief that black men’s tumors are more aggressive is based on studies that failed to match patients properly and used only indirect means to measure tumor aggressiveness.
Every three minutes a man finds out he has prostate cancer — the second-leading cause of cancer death in American men. In fact, more than 218,890 cases are expected in 2007, making prostate cancer among men more prevalent than breast cancer among women.
An increase in high-grade prostate cancer among men taking the drug finasteride is likely caused by an increased detection of cancers, and not by the development of more high-grade cancers, according to two studies published online September 11 in the Journal of the National Cancer Institute.